Non-Hodgkin Lymphoma | Specialty

Treatment in Transplant-ineligible R/R DLBCL

July 15th 2020

Prognosis of R/R DLBCL

July 15th 2020

Standard of Care for Treatment of DLBCL

July 15th 2020

Dr. Abdulhaq on the Benefits of Chemotherapy-Free Options in DLBCL

July 14th 2020

Haifaa Abdulhaq, MD, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma.

Leonard Leads Discussion on Latest Developments in Leukemias and Lymphomas

June 26th 2020

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.

EMA Accepts Application for Zanubrutinib in Waldenström Macroglobulinemia

June 19th 2020

The European Medicines Agency has validated and accepted a marketing authorization application for zanubrutinib for the treatment of patients with Waldenström macroglobulinemia who have received at least 1 prior therapy or as frontline treatment for patients who are ineligible for chemoimmunotherapy.

Dr. Jacobson on Design of ZUMA-5 Trial in R/R Indolent Non-Hodgkin Lymphoma

June 18th 2020

Caron Jacobson, MD, discusses the design of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

FDA Approves Tazemetostat in Relapsed/Refractory Follicular Lymphoma

June 18th 2020

The FDA has approved tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, as well as those with relapsed/refractory disease who have no other available satisfactory treatment options.

Liso-Cel Induces High Response Rates in High-Risk Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 12th 2020

Treatment with the CAR T-cell product lisocabtagene maraleucel led to high response rates, with durable complete responses, in transplant-ineligible patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma who had poor prognostic features.

FDA Grants CLR 131 Fast Track Status for LPL/WM

May 26th 2020

The FDA has granted a Fast Track designation to CLR 131 for use as a treatment for patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.

More Data Needed to Tease Out Optimal Approaches in Non-Hodgkin Lymphoma

May 7th 2020

Sonali M. Smith, MD, sheds light on some of the recent advances in follicular lymphoma and mantle cell lymphoma, as well as the challenges that remain overall in non-Hodgkin lymphoma.

FDA Extends Review Period for Liso-Cel in Large B-Cell Lymphoma

May 6th 2020

The FDA has extended the review period for a biologics license application for lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.

Devimistat Development Progresses in Relapsed/Refractory Burkitt Lymphoma

April 29th 2020

Ariela Noy, MD, discusses the rationale and design of the phase 2 study of devimistat in patients with aggressive lymphoma.

Bispecific Antibody Is Highly Active in Relapsed/Refractory Non-Hodgkin Lymphoma

April 20th 2020

Rajat Bannerji, MD, PhD, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma.

Kahl Weighs the Complexities of Treatment Selection in Indolent Lymphoma

April 15th 2020

Brad S. Kahl, MD, outlines the available treatment options in indolent non-Hodgkin lymphoma, factors that may influence treatment selection, and promising agents on the horizon.

Fresh Options Are Emerging for Relapsed DLBCL

April 7th 2020

Although considerable progress has been made in treating diffuse large B-cell lymphoma since the advent of chemoimmunotherapy, approximately 33% of patients still develop relapsed/refractory disease, which is associated with considerable morbidity and mortality.

FDA Grants ME-401 Fast Track Designation for Follicular Lymphoma

April 1st 2020

The FDA has granted ME-401 Fast Track Designation for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least 2 prior systemic therapies.

FDA Places Partial Hold on Non-Hodgkin Lymphoma Trial

March 11th 2020

The FDA has placed a partial clinical hold on a phase I trial assessing the autologous T-cell therapy ACTR707 in combination with rituximab for patients with CD20-positive, B-cell non-Hodgkin lymphoma due to a safety concern.

FDA Grants Umbralisib Orphan Drug Status in Follicular Lymphoma

March 6th 2020

The FDA has granted an orphan drug designation to umbralisib for the treatment of patients with follicular lymphoma.

Duvelisib Tested in Rare Lymphoma Subtype

March 4th 2020

Investigators propose that a PI3K-δ,γ inhibitor currently indicated for the treatment of 3 hematologic malignancies may be a key to boosting response rates in peripheral T-cell lymphoma, a disease setting defined by poor prognoses.